Syantra, Inc. Partners with Breast Cancer Foundation NZ to Enhance Cancer Detection in New Zealand

Syantra, Inc. and Breast Cancer Foundation NZ Partnership

On October 28, 2025, Syantra, Inc., a cutting-edge biotechnology firm focused on early cancer detection, revealed an important collaboration with Breast Cancer Foundation NZ. This partnership signifies a pivotal move in enhancing Syantra's Onco-ID™ platform, particularly its first cancer detection test, Onco-ID Breast. The collaboration aims to leverage New Zealand's diverse population and established breast cancer screening initiatives, making it a prime location for testing and validating innovative cancer detection methodologies.

Significance of the Partnership

the opportunity for Syantra to work within New Zealand's healthcare framework is substantial. The country features not only a varied demographic but also a supportive research community that welcomes collaboration for clinical studies. Moreover, New Zealand runs a national breast cancer screening program biannually, allowing Syantra's technology to be integrated into real-world healthcare settings effectively. According to Rob Lozuk, CEO of Syantra, this partnership exemplifies their dedication to improving patient care through rigorous clinical validation of their technologies.

The Onco-ID™ Platform

The Onco-ID Breast test is part of Syantra’s innovative Onco-ID platform, which utilizes the immune system's signals to identify active cancer signatures in the body. This advanced technology has been meticulously refined to recognize previously unrecognized changes in normal biological function, enabling early detection of cancer. The partnership with Breast Cancer Foundation NZ is anticipated to pave the way for broader implementation of this sophisticated testing platform, directly influencing outcomes for patients.

Commitment to Local Needs

Dr. Hannah Holtkamp, the Innovation Development Manager at Breast Cancer Foundation NZ, emphasized the importance of tailoring cancer detection solutions to the unique needs of New Zealand's population. The organization is focused on collaborative innovation, seeking equitable solutions to tackle the prevalence of breast cancer. The partnership is underpinned by a shared mission: to eliminate deaths caused by breast cancer, particularly in populations that are often underserved or overlooked.

Syantra’s commitment to investing resources in understanding these unique local needs signifies a dedicated approach to healthcare innovation. The development of accessible screening options, such as the Onco-ID, aims to yield tangible benefits not only in New Zealand but globally.

About Syantra, Inc.

Founded by innovators in biomedical engineering and medicine and backed by leading clinicians, Syantra, Inc. is a privately held precision biotechnology company based in Calgary. The company focuses on redefining cancer detection and management through their groundbreaking technology. More information can be found on their website at Syantra's official website.

About Breast Cancer Foundation NZ

Breast Cancer Foundation NZ plays a crucial role in the fight against breast cancer across the nation. As a non-profit organization, their mission is to minimize mortality linked to breast cancer through comprehensive strategies involving early diagnosis, effective treatment, and swift access to solutions. They actively challenge established healthcare conventions, bridging gaps to transform knowledge into action with the ultimate goal of achieving zero deaths from breast cancer.

Conclusion

The partnership between Syantra, Inc. and Breast Cancer Foundation NZ is a promising advancement in the fight against breast cancer. With mutual dedication to improving healthcare outcomes and expanding access to innovative cancer detection methods, this collaboration represents a hopeful step toward better prevention and treatment options for patients in New Zealand and beyond.